Recombinant NCAM1 (Lorvotuzumab Biosimilar) anticorps
Aperçu rapide pour Recombinant NCAM1 (Lorvotuzumab Biosimilar) anticorps (ABIN7581581)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Expression System
- CHO Cells
-
Fonction
- Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab)
-
Séquence
- QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAY ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARMR KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK,DVVMTQSPLS LPVTLGQPAS ISCRSSQIII HSDGNTYLEW FQQRPGQSPR RLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP HTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
Attributs du produit
- Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Pureté
- >95 %
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Commentaires
-
Therapeutic Agents by Target and Mechanism: CD56 regulators
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- +4°C,-80°C
-
-
- NCAM1 (Lorvotuzumab Biosimilar)
-
Classe de substances
- Biosimilar
-
Poids moléculaire
- 145.5 kDa
-
UniProt
- P13591
Antigène
-